Dupilumab in the treatment of asthma

Alice Grey; Constance H. Katelaris

doi:10.2217/imt-2019-0008

Dupilumab in the treatment of asthma

Alice Grey, Constance H. Katelaris

Western Sydney University

Research output: Contribution to journal › Article › peer-review

Abstract

Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2 (Th2) mediated inflammation. It has already been approved in the USA and Europe for the treatment of atopic dermatitis. Recently, it also gained approval in the USA as add-on treatment for moderate-to-severe asthma in adolescents and adults. Phase II and III randomized controlled trials have demonstrated improvements in asthma exacerbation rates, FEV1, oral glucocorticoid use and a range of patient-reported outcomes, with a favorable safety profile. This article will review the available clinical trial data relating to the efficacy and safety of dupilumab in the management of asthma and related atopic respiratory conditions.

Original language	English
Pages (from-to)	859-872
Number of pages	14
Journal	Immunotherapy
Volume	11
Issue number	10
DOIs	https://doi.org/10.2217/imt-2019-0008
Publication status	Published - 2019

Keywords

asthma
monoclonal antibodies
treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/imt-2019-0008

Cite this

@article{e496bd902bec4cfa8907306228f8bcf5,

title = "Dupilumab in the treatment of asthma",

abstract = "Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2 (Th2) mediated inflammation. It has already been approved in the USA and Europe for the treatment of atopic dermatitis. Recently, it also gained approval in the USA as add-on treatment for moderate-to-severe asthma in adolescents and adults. Phase II and III randomized controlled trials have demonstrated improvements in asthma exacerbation rates, FEV1, oral glucocorticoid use and a range of patient-reported outcomes, with a favorable safety profile. This article will review the available clinical trial data relating to the efficacy and safety of dupilumab in the management of asthma and related atopic respiratory conditions.",

keywords = "asthma, monoclonal antibodies, treatment",

author = "Alice Grey and Katelaris, {Constance H.}",

year = "2019",

doi = "10.2217/imt-2019-0008",

language = "English",

volume = "11",

pages = "859--872",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor & Francis",

number = "10",

}

TY - JOUR

T1 - Dupilumab in the treatment of asthma

AU - Grey, Alice

AU - Katelaris, Constance H.

PY - 2019

Y1 - 2019

N2 - Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2 (Th2) mediated inflammation. It has already been approved in the USA and Europe for the treatment of atopic dermatitis. Recently, it also gained approval in the USA as add-on treatment for moderate-to-severe asthma in adolescents and adults. Phase II and III randomized controlled trials have demonstrated improvements in asthma exacerbation rates, FEV1, oral glucocorticoid use and a range of patient-reported outcomes, with a favorable safety profile. This article will review the available clinical trial data relating to the efficacy and safety of dupilumab in the management of asthma and related atopic respiratory conditions.

AB - Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2 (Th2) mediated inflammation. It has already been approved in the USA and Europe for the treatment of atopic dermatitis. Recently, it also gained approval in the USA as add-on treatment for moderate-to-severe asthma in adolescents and adults. Phase II and III randomized controlled trials have demonstrated improvements in asthma exacerbation rates, FEV1, oral glucocorticoid use and a range of patient-reported outcomes, with a favorable safety profile. This article will review the available clinical trial data relating to the efficacy and safety of dupilumab in the management of asthma and related atopic respiratory conditions.

KW - asthma

KW - monoclonal antibodies

KW - treatment

UR - https://hdl.handle.net/1959.7/uws:52883

U2 - 10.2217/imt-2019-0008

DO - 10.2217/imt-2019-0008

M3 - Article

SN - 1750-743X

VL - 11

SP - 859

EP - 872

JO - Immunotherapy

JF - Immunotherapy

IS - 10

ER -

Dupilumab in the treatment of asthma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this